Brain Tumor Clinical Trials
Brain tumor clinical trials play a vital role in facilitating breakthroughs in care and improving outcomes for patients now and into the future. Individuals who participate in a clinical trial - a controlled research study into a new treatment or methodology - help provide key answers to physicians and scientists regarding the effectiveness of emerging cancer therapies and how they compare to established brain tumor treatments.
Brain tumor clinical trials at Moffitt
Moffitt Cancer Center is making great strides in the fight against brain tumors through our trailblazing clinical trials and research initiatives. Here, patients in our Neuro-Oncology Program have unique opportunities to receive promising new brain tumor therapies before those options are made widely available. We are actively exploring innovations in the prevention, diagnosis and treatment of brain tumors, including:
- Screening and diagnostic strategies
- Targeted therapies
- Chemotherapy combinations and delivery methods
- Immunotherapies
- Vaccine therapies
- Radiation therapies
- Treatment options for benign (noncancerous) brain tumors
- Surgical treatments and robotic-assisted techniques
The types of tumors that we have clinical trials for include:
- Gliomas
- Brain metastasis
- Leptomeningeal disease
- Spinal tumors
The Only Florida-based NCI-designated Comprehensive Cancer Center
Recognized for its scientific excellence, Moffitt is the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida.
Why choose Moffitt?
Moffitt is a nationally recognized leader in clinical trials and research, maintaining one of the largest clinical trial outcome databases in the United States. We have also been awarded multiple grants from the National Cancer Institute, as well as their prestigious Comprehensive Cancer Center designation that speaks to our ambitious approach to cancer research. Moffitt is currently the only Florida-based cancer center to hold this distinction.
Another distinguishing factor of Moffitt is our collaborative approach to brain tumor treatment. The multispecialty team in our brain tumor program works hand in hand to develop individualized treatment plans for patients, which may include clinical trials. Furthermore, our brain tumor specialists focus exclusively on brain cancers and routinely address uncommon and complex cases. This unparalleled expertise, combined with our dedication to research, allows us to help our patients achieve more positive outcomes and better quality of life.
How do I take part in a brain tumor clinical trial?
Your first step toward participating in a brain tumor clinical trial is to speak with a physician about the studies currently available and whether one may be right for you. Clinical trials aren’t appropriate for every patient. Our team prioritizes patient education and will ensure you receive the information you need to make confident decisions about your care.
For further information about brain tumor clinical trials at Moffitt, submit a clinical trial inquiry form online or call 1-813-745-6100 or 1-800-679-0775 (toll-free). Our clinical navigators can discuss your options and answer any questions you may have.
Medically reviewed by Michael Vogelbaum, MD, PhD, Program Leader, Chief of Neurosurgery, Neuro-Oncology Program.
-
Clinical Trials
CLINICAL TRIAL 20110
GBM Agile: Global Adaptive Trial Master Protocol
Condition: Neurologic Oncology
Intervention: ADI-PEG 20 (); AZD1390 (); BAY 73-4506 (Regorafenib); Lomustine (CeeNU); Paxalisib (); Regorafenib (Stivarga); Temodal (Temozolomide); Temozolomide (); Troriluzole (); VAL-083 (); VT1021 ()
CLINICAL TRIAL 20487
Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease
Condition: Breast
Intervention: Herceptin (Trastuzumab); Pertuzumab (); Radiotherapy (); Trastuzumab (); rhuMAb HER2 (Trastuzumab)
CLINICAL TRIAL 20899
Phase I/II Study of Stereotactic Radiation and Abemaciclib with or without Imlunestrant in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases (STRONG Trial)
Condition: Breast
Intervention: Abemaciclib (); Endocrine Therapy (); Imlunestrant (); LY2835219 (Abemaciclib); Radiotherapy ()
CLINICAL TRIAL 21262
A First in Human dose escalation of Dendritic Cell Vaccine (DCV) administered Intrathecally (IT) primed against HER2/HER3 in Patients with Leptomeningeal Disease (LMD) from Triple-Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)
Condition: Neurologic Oncology
Intervention: Dendritic Cell Vaccine ()
CLINICAL TRIAL 22563
A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine (CCNU) or temozolomide (TMZ) in patients undergoing planned resection for first recurrence glioblastoma
Condition: Neurologic Oncology
Intervention: Lomustine (CeeNU); Paraplatin (carboplatin); Temodal (Temozolomide); Temozolomide (); carboplatin ()
CLINICAL TRIAL 23439
A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma
Condition: Neurologic Oncology
Intervention: KPT-330 (Selinexor); Selinexor (); Temodal (Temozolomide); Temozolomide ()
CLINICAL TRIAL 23486
Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases
Condition: Neurologic Oncology
Intervention: Radiotherapy (); fSRS ()
CLINICAL TRIAL 23552
Complications and Management of Neurocutaneous Disorders
Condition: Neurologic Oncology
Intervention:
CLINICAL TRIAL 23773
A Phase 1b/2 Study of AZD0120 (also known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B cell Maturation Antigen in Participants with Relapsed or Refractory AL Amyloidosis
Condition: Malignant Hematology
Intervention: AZD0120 ()
CLINICAL TRIAL 23834
Deciphering the Role of Immune-Related Gene Signature and Tumor-Immune Microenvironment in Glioblastoma
Condition: Neurologic Oncology
Intervention:
Treatment